<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495221</url>
  </required_header>
  <id_info>
    <org_study_id>HOLD STUDY</org_study_id>
    <nct_id>NCT01495221</nct_id>
  </id_info>
  <brief_title>To Evaluate tHe rOle of Intravitreal Aflibercept Injection (2.0 mg) in the Management of previousLy Treated Patients With Exudative AMD</brief_title>
  <official_title>To Evaluate tHe rOle of Intravitreal Aflibercept Injection (2.0 mg) in the Management of previousLy Treated Patients With Exudative AMD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitreous -Retina- Macula Consultants of New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitreous -Retina- Macula Consultants of New York</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal
      aflibercept injection in patients who have been previously treated for AMD and have
      persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with no fluid on OCT at Week 24</measure>
    <time_frame>24 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients no fluid with on OCT at Weeks 12 and 24</measure>
    <time_frame>week 12 and 24</time_frame>
    <description>Mean change in VA from Baseline at Weeks 12, 24 and 48
Mean change in central foveal thickness (RPE to ILM) as measured by SD-OCT at Weeks 12, 24 and 48
Mean change in leakage as determined by FA at Weeks 24 and 48
Mean number of intravitreal aflibercept injections at Week 48
Mean duration of fluid-free interval between Weeks 24 and 48
Mean change in contrast sensitivity at Week 24 and 48
Mean change in microperimetry outcomes at Week 24 and 48
Mean change in NEI VFQ score at Week 48</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>AMD Who Have Persistent or Recurrent Fluid Despite Monthly Intravitreal Anti-VEGF Therapy.</condition>
  <arm_group>
    <arm_group_label>Intravitreal aflibercept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfilbercept</intervention_name>
    <description>All patients will receive 2.0 mg intravitreal aflibercept injection.</description>
    <arm_group_label>Intravitreal aflibercept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 50 years

          -  Choroidal neovascularization secondary to AMD

          -  Best corrected visual acuity in the study eye between 20/25 to 20/400 using an ETDRS
             chart

          -  Documentation of presence of subretinal fluid and/or cystoid macular edema on SD-OCT
             following at least four anti-VEGF treatments within six months before enrollment and a
             maximum of 5 years of years of treatment for neovascular AMD

          -  Documentation of presence of subretinal fluid and/or cystoid macular edema less than
             30 days since last treatment

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or lactation

          -  Premenopausal women not using adequate contraception. The following are considered
             effective means of contraception: surgical sterilization or use of oral
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction
             with spermicidal gel, an IUD, or contraceptive hormone implant or patch.

          -  Participation in another simultaneous medical investigation or trial

          -  Prior treatment with anti-VEGF therapy in the study eye within 30 days of BSL

          -  Prior treatment with PDT within the past 3 months or more than 4 prior PDT treatments.

          -  Presence of significant subfoveal fibrosis or atrophy.

          -  Prior treatment with intravitreal aflibercept injection

          -  Prior treatment with triamcinolone in the study eye within 6 months of BSL.

          -  Prior treatment with dexamethasone in the study eye within 30 days prior to BSL

          -  Intraocular surgery (including cataract surgery) in the study eye within 2 months
             preceding BSL

          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for
             AMD in the study eye

          -  Active intraocular inflammation (grade trace or above) in the study eye

          -  Current vitreous hemorrhage in the study eye

          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the
             study eye

          -  Ocular or periocular infection

          -  Active severe intraocular inflammation

          -  Uncontrolled glaucoma in the study eye (defined as IOP â‰¥ 30 mmHg despite treatment
             with anti-glaucoma medication)

          -  History of cerebral vascular accident, myocardial infarction, transient ischemic
             attacks within 3 months of study enrollment.

          -  History of allergy to fluorescein, ICG or iodine, not amenable to treatment

          -  Known hypersensitivity to aflibercept or to any of the excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vitreous Retina Macula Consultants of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>August 22, 2017</submitted>
    <returned>September 18, 2017</returned>
    <submitted>December 20, 2017</submitted>
    <returned>January 19, 2018</returned>
    <submitted>May 1, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

